---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124616"
form_type: "8-K"
ticker: "ZBIO"
cik: "0001953926"
company_name: "Zenas BioPharma, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T12:13:02.193999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zenas provides obexelimab trial updates: Ph3 INDIGO topline end-2025, Ph2 data 2025-2026

## Summary
- Phase 3 INDIGO trial in IgG4-RD fully enrolled (over 190 patients); topline results expected year-end 2025.
- Phase 2 MoonStone trial in RMS enrolling; 12-week primary endpoint data expected Q3:2025.
- Phase 2 SunStone trial in SLE enrolling; 24-week primary endpoint data expected 1H:2026.
- Preliminary interim data from Cohort 1 of Phase 2 SApHiAre trial in wAIHA provided.
- Company states capitalized for clinical data readouts into Q4:2026.

## SEC filing metadata
- accession: 0001104659-24-124616
- form_type: 8-K
- ticker: ZBIO
- cik: 0001953926
- company_name: Zenas BioPharma, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/0001104659-24-124616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/tm2429902d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124616
- JSON: https://secwatch.observer/filing/0001104659-24-124616.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.